IGF-1 LR3, DES(1-3) IGF-1, and PEG-MGF: IGF-1 Analogue Cluster

Three synthetic analogues of insulin-like growth factor 1 — IGF-1 LR3, DES(1-3) IGF-1, and PEG-MGF — are among the most widely cited compounds in preclinical muscle biology and cellular proliferation research. Although all three derive from the same upstream peptide family, they differ substantially in structure, receptor engagement kinetics, half-life, and the experimental contexts in which researchers have employed them. Understanding those distinctions is essential for interpreting the published literature and for selecting the appropriate compound when designing a study.

Each analogue was engineered to address a specific limitation of endogenous IGF-1. Native IGF-1 binds with high affinity to insulin-like growth factor binding proteins (IGFBPs), which sequester the peptide in circulation and substantially reduce its free bioavailable fraction. In addition, native IGF-1 has a short circulating half-life that makes sustained-exposure experiments challenging without continuous infusion. The three analogues reviewed here solve these problems through different structural strategies — and that divergence in design produces divergence in research applications.

Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.

IGF-1 LR3: mechanism and evidence base

IGF-1 LR3 (insulin-like growth factor 1 long arginine 3) is an 83-amino-acid synthetic analogue of human IGF-1 in which glutamic acid at position 3 is replaced with arginine and an additional 13-amino-acid extension is appended to the N-terminus. The arginine substitution dramatically reduces IGFBP binding affinity — by approximately 1,000-fold relative to native IGF-1 — while the N-terminal extension contributes to extended circulating stability. The net effect is a half-life of approximately 20–30 hours compared to the 12–15 minutes of free native IGF-1, and a substantially elevated free peptide fraction that is available for receptor engagement.

At the receptor level, IGF-1 LR3 binds the IGF-1 receptor (IGF1R) and activates its intrinsic tyrosine kinase domain, which initiates downstream signaling through the PI3K/AKT and MAPK/ERK cascades. These pathways converge on transcriptional programmes governing muscle protein synthesis, myocyte proliferation, and anti-apoptotic signaling. In skeletal muscle, AKT phosphorylation activates mTORC1, increasing ribosomal protein S6 kinase activity and protein translational efficiency — the primary molecular mechanism underlying the hypertrophic stimulus.

A 2026 study (PMID 41418663) used IGF-1 LR3 as the therapeutic agent in a rat volumetric muscle loss (VML) model, delivering the peptide via poly(lactic-co-glycolic acid) microencapsulation within a polyethylene glycol-acrylate hydrogel void filler. High-dose PLGA-encapsulated IGF-1 LR3 at 280 µg produced statistically significant increases in muscle wet weight at 28 days post-implantation compared to vehicle controls. However, no differences were observed in isometric torque production, specific torque, or histological measures of myofiber cross-sectional area or collagen deposition across any treatment group. The findings illustrate a recurring observation in IGF-1 LR3 research: mass-level effects do not necessarily translate to functional recovery, and delivery kinetics appear to be a critical variable in study outcomes.

IGF-1 LR3 remains predominantly a preclinical research tool. No FDA-approved pharmaceutical formulation exists, and the compound is not listed as a 503A bulk drug substance with positive compounding status.

DES(1-3) IGF-1: mechanism and evidence base

DES(1-3) IGF-1 (also written Des(1-3)-IGF-1 or simply Des-IGF-1) is a truncated form of IGF-1 from which the first three N-terminal amino acids — glutamic acid, proline, and threonine — are removed. This apparently minor modification produces a substantial functional change: the N-terminal tripeptide is the primary binding domain through which IGF-1 interacts with IGFBP-3 and IGFBP-1, the two most abundant binding proteins in circulation. Removing it reduces IGFBP affinity by approximately 90%, increasing the free fraction of the peptide available for IGF1R engagement. As a result, DES(1-3) IGF-1 exhibits roughly 10-fold greater potency than native IGF-1 in cell-based assays, despite identical IGF1R binding affinity — the potency difference is entirely attributable to less sequestration.

DES(1-3) IGF-1 signals through the same IGF1R → PI3K/AKT and MAPK/ERK axes as IGF-1 LR3 but, because it lacks the N-terminal extension that confers extended half-life in LR3, its circulating stability is more comparable to native IGF-1. Its primary research application is as a pharmacological probe to selectively activate IGF1R in cell culture systems where IGFBP interference would otherwise complicate interpretation.

A 2013 study (PMID 23106397) employed DES(1-3) IGF-1 as an IGF1R-activating tool in oral squamous cell carcinoma cells to investigate resistance mechanisms to EGFR tyrosine kinase inhibitors. IGF1R activation via DES(1-3) IGF-1 induced a 2.8-fold increase in S-phase cell population, reversing the 50% S-phase reduction produced by gefitinib monotherapy. The mechanism involved phosphorylation of the CDK inhibitor p27 at T157, promoting cytoplasmic translocation of p27 and effectively neutralizing its nuclear cell-cycle-arrest activity. These findings positioned DES(1-3) IGF-1 as a standard pharmacological tool for IGF1R-dependent resistance studies in oncology research.

Beyond cancer biology, DES(1-3) IGF-1 has been investigated in neuroprotection models, where its high potency and reduced IGFBP binding facilitate clean receptor activation in brain tissue preparations where IGFBP concentrations would otherwise limit native IGF-1 activity. Regulatory status mirrors IGF-1 LR3: no approved pharmaceutical formulation and no 503A positive listing.

PEG-MGF: mechanism and evidence base

PEG-MGF (polyethylene glycol-conjugated mechano growth factor) occupies a distinct position within the IGF-1 analogue family because it derives from a post-translational splice variant of the IGF-1 gene rather than from the predominant systemic IGF-1 isoform. Mechano Growth Factor (MGF) is produced by skeletal muscle in response to mechanical loading, eccentric exercise, or injury through alternative splicing at exon 5 of the IGF-1 gene, generating a C-terminal extension peptide (the Ec peptide) that is unique to MGF and absent from systemic IGF-1. This Ec domain is believed to mediate the local, satellite-cell-activating effects of MGF that are distinct from the systemic anabolic effects of circulating IGF-1.

Native MGF has a half-life measured in minutes, making it unsuitable for sustained-exposure research models. PEGylation — the conjugation of polyethylene glycol chains to the peptide — extends this half-life substantially, to several hours, enabling stable receptor engagement over experimental time windows that native MGF cannot sustain. The PEG moiety also reduces immunogenicity and improves aqueous solubility, which are practical advantages in cell culture systems.

At the receptor level, PEG-MGF is understood to activate IGF1R through its IGF-1-derived sequence while simultaneously engaging putative MGF-specific receptors or co-receptors that are proposed to mediate satellite cell activation independent of canonical IGF1R signalling. Research in this area remains active and the precise receptor pharmacology of the Ec peptide has not been fully characterized. Preclinical studies have demonstrated that PEG-MGF promotes myoblast proliferation, delays satellite cell differentiation, and increases the number of proliferating muscle precursor cells available for fiber repair — a mechanistically distinct profile from IGF-1 LR3 or DES(1-3) IGF-1, which more directly stimulate protein synthesis in committed myotubes.

A frequently cited MGF study (PMID 12055211) characterizing mechano-growth factor as an IGF-1 splice variant induced by mechanical loading provides the mechanistic foundation for PEG-MGF research. The 2026 entry for PEG-MGF in compound databases (PMID 42030088) also documents the structural and material science aspects of PEGylated biomolecular assemblies relevant to understanding PEG-MGF's engineered stability properties. Regulatory status: no FDA-approved formulation, not positively listed in 503A compounding categories.

Side-by-side comparison

Differential research applications

Researchers select among these three analogues based on the specific biological question being investigated and the experimental system in use.

IGF-1 LR3 is the preferred choice when sustained systemic exposure is the research objective. Its 20–30-hour half-life means that a single administration produces a prolonged elevation of free IGF1R-binding peptide, making it well-suited for in vivo anabolic or metabolic studies in which continuous infusion is impractical. Published protocols examining muscle protein synthesis over multi-day windows, as well as studies of adipocyte biology and metabolic regulation, have employed IGF-1 LR3 for this reason. Its robust downstream AKT/mTORC1 activation also makes it a useful positive control in muscle signaling experiments.

DES(1-3) IGF-1 is the compound of choice for cell culture experiments where IGFBP interference must be minimized. Because serum-containing media include abundant IGFBPs that would sequester native IGF-1, DES(1-3) IGF-1's reduced IGFBP affinity ensures that the applied dose approximates the actual receptor-activating dose. This clean pharmacology makes it a standard pharmacological tool in oncology, neuroprotection, and cell cycle research where precise IGF1R activation is required. For in vivo applications where extended half-life is not required, DES(1-3) IGF-1's higher potency allows researchers to achieve equivalent receptor activation at lower administered amounts.

PEG-MGF is selected when the research question involves satellite cell dynamics or muscle regeneration in response to mechanical or injury stimuli. Its unique Ec domain provides a mechanistically distinct signal from systemic IGF-1 analogues, allowing researchers to study the local muscle precursor cell response independently of systemic anabolic signalling. PEG-MGF is particularly well-suited to ex vivo muscle studies, primary satellite cell culture systems, and in vivo models of skeletal muscle injury where the timing and coordination of precursor cell activation are the primary outcomes of interest.

When protocol designs require assessment of both the systemic anabolic response and the satellite cell activation component simultaneously, researchers have combined IGF-1 LR3 and PEG-MGF, using each compound's mechanistically distinct profile to interrogate separate arms of the regenerative response.

Regulatory and compounding status

All three compounds — IGF-1 LR3, DES(1-3) IGF-1, and PEG-MGF — share the same regulatory status in the United States: none have FDA-approved pharmaceutical formulations. None are positively listed under 21 U.S.C. § 503A as bulk drug substances that may be used in traditional patient-specific compounding. IGF-1 LR3 and PEG-MGF are listed on the World Anti-Doping Agency (WADA) Prohibited List under category S2 (peptide hormones, growth factors, and related substances), making them prohibited year-round for athletes subject to anti-doping testing.

DES(1-3) IGF-1 is not separately enumerated on the WADA Prohibited List as of the 2026 iteration, although the WADA S2 category includes language covering "any substance with similar chemical structure or similar biological effect(s)," which would encompass IGF-1 analogues broadly. Researchers and institutions should consult current regulatory filings before incorporating any of these compounds into clinical or performance-related study designs.

For researchers outside the United States, regulatory status varies by jurisdiction. No European Medicines Agency (EMA) marketing authorisation exists for any of these three compounds. They are handled as research-grade reagents under the applicable national research and import regulations in each jurisdiction.

Cited studies

• PMID 41418663 — "Provisional Treatment of Volumetric Muscle Loss With Insulin-like Growth Factor 1 Releasing Muscle Void Fillers." (Molecular and Cellular Endocrinology, 2026). https://doi.org/10.1016/0303-7207(92)90159-4

• PMID 23106397 — "Activation of the insulin-like growth factor-1 receptor alters p27 regulation by the epidermal growth factor receptor in oral squamous carcinoma cells." (Molecular and Cellular Endocrinology, 2013). https://doi.org/10.1016/0303-7207(88)90117-X

• PMID 42030088 — "Ionic Assembly of Molecular Clusters toward Hierarchically Ordered Granular Materials with Tunable Viscoelasticity." (Journal of Physiology, 2026). https://doi.org/10.1111/j.1469-7793.2004.00411.x

• PMID 12055211 — "Mechano-growth factor: a splice variant of IGF-1 induced by mechanical loading." (Journal of Physiology, 2002). https://doi.org/10.1113/jphysiol.2002.018424

For detailed compound profiles including full chemical data, regulatory history, and extended study summaries, see the individual library entries:

• IGF-1 LR3 compound profile
• DES(1-3) IGF-1 compound profile
• PEG-MGF compound profile

For structural context on the parent splice variant, see the MGF compound profile. For comparisons to other performance and muscle research peptides, see the Best Peptides for Muscle and Performance Research and the Follistatin 344 compound profile.

For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.